Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome

Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome

Objectives: Intravesical Bacillus Calmette-Guérin (BCG) treatment for superficial bladder cancer is interrupted in approximatively 8% of cases as a result of complications. The objective is to report the severe related complications of Bacillus Calmette-Guérin (BCG) following an intravesical instill...

Full description

Bibliographic Details
Main Authors:	R. Waked, J. Choucair, N. Chehata, E. Haddad, G. Saliba
Format:	Article
Language:	English
Published:	Elsevier 2020-05-01
Series:	Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Subjects:	Mycobacterial infection Intravesical Bacillus Calmette-Guérin Bacillus Calmette-Guerin Urothelial bladder cancer Severe complication Treatment protocol
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405579420300073

Similar Items

Bacillus Calmette-Guerin (BCG) infections following intravesical BCG immunotherapy: a systematic review protocol
by: Roberta Monardo, et al.
Published: (2025-01-01)

Bacillus Calmette-Guérin pneumonitis after intravesical instillation: Report of two cases and a review of the literature
by: Martina Spisarova, et al.
Published: (2024-06-01)

New-onset guttate psoriasis following intravesical immunotherapy of Bacillus Calmette–Guerin
by: Chih-Tsung Hung, et al.
Published: (2012-09-01)

Penile lesion with inguinal adenopathy after intravesical Bacillus Calmette-Guerin instillation therapy
by: Guven Aslan, et al.
Published: (2013-01-01)

Impact of intravesical Bacillus Calmette-Guérin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer
by: Christopher James, et al.
Published: (2023-04-01)

Saudi urologists’ treatment pattern for high-risk Bacillus Calmette–Guérin naïve and Bacillus Calmette–Guérin unresponsive nonmuscle invasive bladder cancer
by: Mohammad Alghafees, et al.
Published: (2025-01-01)

Intravesical bacillus Calmette-Guerin (BCG) in treating non-muscle invasive bladder cancer—analysis of adverse effects and effectiveness of two strains of BCG (Danish 1331 and Moscow-I)
by: Yuvaraja B. Thyavihally, et al.
Published: (2022-04-01)

Granulomatous Hepatitis Following Intra-Vesical Instillation of Bacillus Calmette–Guérin for Treatment of Bladder Cancer
by: Elsa Alves Branco, et al.
Published: (2021-07-01)

The impact of Bacillus Calmette-Guérin (BCG) vaccination on the course of COVID-19
by: Jakub Krzysztof Gałązka
Published: (2022-10-01)

Bacillus Calmette-Guérin Spondylodiscitis after Intravesical BCG Therapy: A Case Report
by: Akihito Kawai, et al.
Published: (2022-11-01)

Economic impacts of the Bacillus Calmette-Guérin (BCG) therapy shortage and the proposed solutions for patients with non-muscle invasive bladder Cancer in Aseer Province, Saudi Arabia
by: Mishari H M Alshyarba, et al.
Published: (2020-01-01)

Weekly intravesical bacillus Calmette-Guerin (BCG) alternating with epirubicin in Ta and T1 urothelial bladder cancer: An approach to decrease BCG toxicity
by: Bedeir Ali-El-Dein, et al.
Published: (2013-01-01)

Bacillus Calmette-Guerin Increases Base Excision Repair in Bladder Cancer Cells
by: Selçuk Keskin, et al.
Published: (2021-03-01)

A case of Mycobacterium bovis Bacillus Calmette-Guérin (BCG) strain meningitis and ventriculitis following BCG vaccination
by: Mihoko Furuichi, et al.
Published: (2020-11-01)

Assessment of angiogenic factor, vascular endothelial growth factor, serum and urine level changes in superficial bladder tumor immunotherapy by intravesical Bacillus Calmette-Guerin
by: Kerigh Behzad, et al.
Published: (2010-01-01)

Regression of the Sweet's syndrome after Bacillus Calmette-Guérin therapy: A bladder cancer case report
by: İbrahim Halil Baloglu, et al.
Published: (2020-07-01)

Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes
by: Wei Shen Tan, et al.
Published: (2023-07-01)

Successful treatment of anogenital warts with single dose Bacillus Calmette Guerin vaccine without prior sensitization in tuberculosis endemic country: Two case report
by: Pati Aji Achdiat, et al.
Published: (2023-01-01)

Intralesional Avirulent Bacillus Calmette-Guérin Injection as a Promising Method for the Treatment of Tuberculosis Verrucosa Cutis
by: Özgür Gündüz, et al.
Published: (2022-03-01)

Disseminated BCG sepsis following intravesical therapy for Bladder Carcinoma: A case report and review of literature
by: Oreoluwa Oladiran, et al.
Published: (2020-03-01)

First vaccination after birth: serious adverse events of Bacillus Calmette-Guérin (BCG) in real-world
by: Jinmiao Lu, et al.
Published: (2022-11-01)

Adverse reactions due to the bacillus Calmette-Guerin vaccine: Twenty Tunisian cases
by: Khadija Sellami, et al.
Published: (2018-01-01)

Measles infection causing Bacillus Calmette-Guérin reactivation: a case report
by: Sobana Muthuvelu, et al.
Published: (2019-07-01)

Partial Versus Complete Bacillus Calmette-Guérin Intravesical Therapy and Bladder Cancer Outcomes in High-risk Non–muscle-invasive Bladder Cancer: Is NIMBUS the Full Story?
by: Michael E. Rezaee, et al.
Published: (2021-04-01)

Antibiotic therapy impact on intravesical BCG therapy efficacy for high-risk localized bladder cancer treatment
by: Cécile Aubert, et al.
Published: (2024-03-01)

Bacillus Calmette–Guerin intravesical instillation therapy-induced urothelial necrosis of the bladder and upper urinary tract
by: Tsubasa Kondo, et al.
Published: (2022-09-01)

Safety profiles of intravesical Bacillus Calmette-Guerin in bladder cancer
by: Yun Peng, et al.
Published: (2024-12-01)

Efficacy of bladder instillations with mitomycin or bacillus Calmette–Guérin in patients with T1 high-grade bladder cancer: Experience from a single center
by: Li-Wen Chang, et al.
Published: (2019-01-01)

A randomized trial comparing low dose (40 or 80 mg) with standard dose (120 mg) of bacillus Calmette-Guerin for superficial bladder cancer
by: Vivek Vijjan, et al.
Published: (2006-01-01)

Bacillus calmette–Guérin scar inflammation after COVID vaccination
by: B N Shiva Prasad
Published: (2022-01-01)

Childhood lupus vulgaris after Bacillus Calmette–Guérin vaccine
by: Sarah Hamdy Soliman, et al.
Published: (2023-01-01)

<italic>Mycobacterium</italic> bovis Associated Aneurysm of the Common Iliac Artery After Bacillus Calmette-Guérin Intravesical Treatment for Urothelial Carcinoma
by: Davide Voci, et al.
Published: (2022-12-01)

Bacillus Calmette-Guérin (BCG)-Vaccine Is it giving a protection against SARS-CoV-2?
by: Mehnaz Tanveer, et al.
Published: (2022-06-01)

Tuberculosis Epididymo-Orchitis Mimicking Malignancy Resulting from Intravesical Bacillus Calmette–Guérin Immunotherapy for Bladder Cancer: A Case Report of a Rare Complication
by: Liang-Wei Chiu, et al.
Published: (2022-11-01)

Systemic granulomatous reaction secondary to treatment of bladder cancer with Bacillus Calmette-Guerin
by: Caterina Giovanna Valentini, et al.
Published: (2012-06-01)

Systemic granulomatous reaction secondary to treatment of bladder cancer with Bacillus Calmette-Guerin
by: Caterina Giovanna Valentini, et al.
Published: (2012-01-01)

Polymyalgia rheumatica following intravesical bacillus Calmette-Guerin instillation: coincidence or true association? A case report and literature review
by: Ciro Manzo
Published: (2020-03-01)

Dual Bacillus Calmette–Guerin vaccination along the border communities of Angola and Namibia
by: Abubakar Sadiq Umar, et al.
Published: (2016-01-01)

Recurrence and progression in nonmuscle invasive transitional cell carcinoma of urinary bladder treated with intravesical Bacillus Calmette–Guerin: A single center experience and analysis of prognostic factors
by: Shouki N Bazarbashi, et al.
Published: (2016-01-01)

A single strain of Mycobacterium bovis bacillus Calmette-Guérin (BCG) grown in two different media evokes distinct humoral immune responses in mice
by: V.L. Petricevich, et al.
Published: (2001-01-01)